Essilor® recently unveiled new six-year clinical data of Essilor® Stellest® lenses, reinforcing the long-term efficacy of the lenses in managing myopia progression and axial elongation in children and young adults. The results underscore the significant and sustained impact of Essilor® Stellest® lenses in controlling myopia progression, offering valuable insights into strategies for addressing the global myopia epidemic.

The study began in 2018 with children aged between 8 and 13 years old. After completing the initial five-year phase, participants continued wearing Essilor® Stellest® lenses for an additional two years to assess the long-term impact on myopia progression. By the time of the sixth-year follow-up, the participants were aged between 14 and 19 years. The six-year results showed that Essilor® Stellest® lenses slowed myopia progression by 1.95 D (57%) and slowed axial elongation by 0.81 mm (52%)1 on average, compared to an extrapolated single-vision lens control group* model based on data from the first two years of the clinical trial. The findings demonstrate the continued efficacy of Essilor® Stellest® lenses, with effects sustained up to 19 years of age.

“The positive response from eye care professionals highlights the widespread adoption of Essilor® Stellest® lenses as a trusted, proven tool for them worldwide, supporting long-term myopia management, while addressing the global myopia epidemic,” said Olga Prenat, Head of Medical & Professional Affairs at EssilorLuxottica. “These results reinforce EssilorLuxottica’s commitment to advancing myopia management with innovative solutions that have a lasting impact on children’s long-term eye health.”

In addition, five-year efficacy data recently published in Eye and Vision demonstrated that Essilor® Stellest® lenses significantly slowed myopia progression and axial elongation over five years, *2 saving an average of three years of myopia development† 2,3. The study also showed that the risk of progressing to high myopia (defined as -6 D or worse) dropped from 38% in the extrapolated single-vision lens control group to just 9% in the Essilor® Stellest® lenses group2. This research further validates the ethical approach of using extrapolated control groups in long-term clinical trials evaluating myopia progression.

Dr. Björn Drobe, Director, Applied Myopia Research, EssilorLuxottica R&D, commented, “The six-year clinical data, along with other recent published studies, represent a significant step forward in understanding the full scope of how Essilor® Stellest® lenses manage myopia progression, further confirming their long-term efficacy and significant role in myopia management.”

Essilor® Stellest® lenses provide eye care practitioners with an evidence-backed solution for managing myopia in children and young adults. With robust clinical data supporting their efficacy, these lenses offer a reliable approach for helping families address the challenges of myopia, improving both short- and long-term eye health outcomes.

For further press information, please contact Bianca Taylor at bianca.taylor@essilor.ca

About Essilor®:

Essilor®, part of EssilorLuxottica’s portfolio, is a leader in eyeglass lenses worldwide (4) and the number one lens brand recommended by eye care professionals (ECP).(5) It offers a complete range of solutions dedicated to each individual’s vision and lifestyle needs throughout their life. Every Essilor® lens is a combination of multiple complementary technologies thanks to its suite of leading premium vision care solutions, including innovative brands such as Stellest®, Eyezen® and Varilux®and Crizal®. These groundbreaking technologies correct vision, protect eyes from UV rays and enhance visual clarity.

References

Essilor Stellest lenses are currently not available in all countries.

*Compared to the 60-month progression of the extrapolated control group (predicted average annual decrease in SER by 9.7% based on the initial 2-year control group, Smotherman C, et al. IOVS 2023;64:ARVO E-Abstract 811) & Compared to the 60-month progression of the extrapolated control group (predicted average annual decrease in AL by 15% based on the initial 2-year control group, Shamp W, et al. IOVS 2022;63:ARVO E-Abstract A0111)

†The initial 24-month myopia progression of 50 myopic children wearing single vision lenses in the two-year prospective, controlled, randomized, double-masked clinical in Wenzhou China were compared to the 60-month follow-up of 43 children wearing Essilor® Stellest® lenses.

1. EssilorLuxottica. Myopia control efficacy of spectacle lenses with highly aspherical lenslets: results of a 6-year follow-up study. 2025. Data on file.

2. Li X, Huang Y, Liu C, Chang X, Cui Z, Yang Q, Drobe B, Bullimore MA, Chen H, Bao J. Myopia control efficacy of spectacle lenses with highly aspherical lenslets: results of a 5-year follow-up study. Eye and Vision. 2025 Mar 5;12(1):10.

3. Bao J, Huang Y, Li X, Yang A, Zhou F, Wu J, Wang C, Li Y, Lim EW, Spiegel DP, Drobe B, Chen, H. Spectacle lenses with aspherical lenslets for myopia control vs single-vision spectacle lenses: a randomized clinical trial. JAMA ophthalmology. 2022;140(5):472-8

4. Euromonitor, Eyewear 2024 edition; Essilor International company; worldwide retail value sales at RSP.

5. Based on an average recommendation with quantitative research conducted in 8 countries (Brazil, Canada, China, France, India, Italy, UK, and the US) among a representative sample of 1560 Eye Care Professionals: 1047 opticians, 513 optometrists, between January and June 2022. These 8 countries represent: 63% of total world in lens volume.